Skip to main content

Closed

KRYS: Krystal Biotech, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Strong

Revenue growth+473.0% / yr

Operating margin42.8%

ROIC13.9%

Financially safe

Stretched

Debt / equity0.01×

Interest coverage0.0×

Current ratio9.46×

Valuation

Unrated

P/E ratio44.0×

Krystal Biotech, Inc.

KRYSNASDAQ Global Market·USD·Closed

Krystal Biotech, Inc.

KRYSNASDAQ·USD·Closed

$341.12

−7.01%

$341.12

−$25.73 (7.01%)

52W Range

84thpctl

Volume

1.13×avg

Mkt Cap

10.06BUSD

P/E

44.0TTM

Div Yield

–ann

52W Range

84thpctl

Volume

1.13×avg

Market Cap

10.06BUSD

P/E Ratio

44.0TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings